Trial Profile

Secondary Prevention in Coronary Heart Disease.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza virus vaccine (Primary) ; ACE inhibitors; Angiotensin type 1 receptor antagonists; Antihyperglycaemics; Atorvastatin; Beta adrenergic receptor antagonists; Cardiovascular therapies; Diuretics; Ezetimibe; Glimepiride; HMG-CoA reductase inhibitors; Insulin; Metformin; Moxonidine; Nicotine replacement therapy; Simvastatin; Varenicline
Indications Coronary artery disease
Focus Therapeutic Use
Acronyms SPREK!

Most Recent Events

16 Mar 2021 Status changed from active, no longer recruiting to completed.
08 Aug 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2024 as reported by ClinicalTrials.gov record.
08 Aug 2017 Planned Primary completion date changed fr5om 1 Dec 2016 to 1 Dec 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com